Pyxis Oncology

Overview

Pyxis Oncology is a clinical-stage biotechnology company developing next-generation immunotherapies that target the tumor microenvironment and modulate innate immune pathways. While primarily focused on oncology, the company's NLRP3 program has significant implications for neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2019 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Matthew Maurer |
| IPO | Nasdaq (NASDAQ: PYXS), 2023 |
| Focus | Immunotherapy, NLRP3 inhibitors |
| Stage | Phase 1/Preclinical |

History

Pyxis Oncology was founded based on research from the Dana-Farber Cancer Institute and Massachusetts General Hospital. The company's initial focus was on cancer immunotherapy, particularly antibodies targeting CD47 and related "don't eat me" signals.

In 2022, Pyxis expanded its pipeline to include NLRP3 inflammasome inhibitors, recognizing the role of neuroinflammation in both cancer metastasis to the brain and primary neurodegenerative diseases.

Science and Technology

NLRP3 Program

Pyxis's NLRP3 program is distinct from its oncology focus but leverages the same scientific expertise:

• Target: NLRP3 NACHT domain inhibition
• Approach: Small molecules that block inflammasome assembly
• Application: Both cancer immunotherapy and neurodegeneration

Pipeline Overview

...

Overview

Pyxis Oncology is a clinical-stage biotechnology company developing next-generation immunotherapies that target the tumor microenvironment and modulate innate immune pathways. While primarily focused on oncology, the company's NLRP3 program has significant implications for neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2019 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Matthew Maurer |
| IPO | Nasdaq (NASDAQ: PYXS), 2023 |
| Focus | Immunotherapy, NLRP3 inhibitors |
| Stage | Phase 1/Preclinical |

History

Pyxis Oncology was founded based on research from the Dana-Farber Cancer Institute and Massachusetts General Hospital. The company's initial focus was on cancer immunotherapy, particularly antibodies targeting CD47 and related "don't eat me" signals.

In 2022, Pyxis expanded its pipeline to include NLRP3 inflammasome inhibitors, recognizing the role of neuroinflammation in both cancer metastasis to the brain and primary neurodegenerative diseases.

Science and Technology

NLRP3 Program

Pyxis's NLRP3 program is distinct from its oncology focus but leverages the same scientific expertise:

• Target: NLRP3 NACHT domain inhibition
• Approach: Small molecules that block inflammasome assembly
• Application: Both cancer immunotherapy and neurodegeneration

Pipeline Overview

| Program | Mechanism | Indication | Stage | Status |
|---------|-----------|------------|-------|--------|
| PYX-001 | Anti-CD47 antibody | Solid tumors | Phase 1 | Recruiting |
| PYX-002 | NLRP3 inhibitor | Parkinson's disease | Preclinical | Lead optimization |
| PYX-003 | SIRPα Fc fusion | Hematologic cancers | Phase 1 | Active |
| PYX-004 | NLRP3/TGF-β dual | Fibrosis | Discovery | Early stage |

PYX-002 (Parkinson's Disease)

PYX-002 is Pyxis's lead program for Parkinson's disease:

• Mechanism: Direct NLRP3 inhibition
• Selectivity: High selectivity for NLRP3 over other NLRs
• BBB penetration: Optimized for brain exposure
• Rationale: Block neuroinflammation without compromising anti-tumor immunity

The company's oncology expertise informs its understanding of immune modulation in the brain tumor microenvironment, which shares features with neuroinflammation in PD.

Technology Platform

Pyxis's technology platform includes:

Antibody engineering: Fc optimization for enhanced efficacy

Small molecule discovery: Structure-based design of NLRP3 inhibitors

Combination therapy: Rational combinations of immunotherapies

Clinical Development

Oncology Programs

PYX-001 (anti-CD47) is currently in Phase 1 clinical trials for solid tumors:

• Mechanism: Blocks CD47-SIRPα "don't eat me" signal
• Rationale: Enable macrophage phagocytosis of tumor cells
• Status: Dose-escalation ongoing

Neurodegeneration Strategy

For PYX-002 (Parkinson's disease), Pyxis plans:

Preclinical package: GLP toxicology, PK/PD studies

Patient selection: Biomarkers for NLRP3-driven inflammation

Phase 1/2 design: Safety and biomarker-driven efficacy

Intellectual Property

Pyxis has built a strong IP portfolio around its programs:

• NLRP3 inhibitors: Multiple patent families covering composition of matter and methods of use
• Anti-CD47 antibodies: Fc-optimized variants with enhanced activity
• Combination therapies: NLRP3 inhibitors with checkpoint inhibitors

Financials

| Metric | Value |
|--------|-------|
| IPO date | October 2023 |
| IPO price | $16.00/share |
| Market cap (2024) | ~$150M |
| Cash runway | Through 2025 |
| Revenue | None (R&D stage) |

Competitive Position

Pyxis occupies a unique position with both oncology and neurodegeneration programs:

| Company | Focus | Pyxis Differentiation |
|---------|-------|----------------------|
| Olacteant | NLRP3 (Dapansutrile) | Clinical data, single target |
| NodThera | NLRP3 (NT-0796) | CNS focus, Phase 1 |
| Ventus | NLRP3 + Gasdermin | Dual mechanism |
| Pyxis | NLRP3 + CD47 | Platform approach |

Research Pipeline

gantt
title Pyxis NLRP3 Program Timeline
dateFormat YYYY
axisFormat %Y

section PYX-002
Lead optimization :active, 2023, 2025
IND-enabling :2025, 2026
Phase 1 :2026, 2027

References

[Pyxis Oncology Website](https://www.pyxisoncology.com)

[SEC Filing](https://www.sec.gov)

[Broz P et al., NLRP3 inflammasome inhibition (2019)](https://pubmed.ncbi.nlm.nih.gov/31745341/)

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [Ventus Therapeutics](/companies/ventus-therapeutics)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)